Astaxanthin lowers plasma TAG concentrations and increases hepatic antioxidant gene expression in diet-induced obesity mice

British Journal of Nutrition

Volumn 112, Issue 11, 2014, Pages 1797-1804

  Yang, Yue ^a   Pham, Tho X ^a   Wegner, Casey J ^a   Kim, Bohkyung ^a   Ku, Chai Siah ^a   Park, Young Ki ^a   Lee, Ji Young ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Antioxidants; Astaxanthin; Diet induced obesity mice; Hypotriacylglycerolaemia; Non alcoholic fatty liver disease

Indexed keywords

ACYL COENZYME A OXIDASE; ACYL COENZYME A OXIDASE 1; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ASTAXANTHIN; DIACYLGLYCEROL ACYLTRANSFERASE 2; FATTY ACID SYNTHASE; MESSENGER RNA; TRANSCRIPTION FACTOR NF E2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIOXIDANT; NFE2L2 PROTEIN, MOUSE; TRANSCRIPTION FACTOR NRF2; XANTHOPHYLL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG MECHANISM; ENZYME BLOOD LEVEL; GENE EXPRESSION; IL 6 GENE; INFLAMMATION; MALE; MOUSE; NONHUMAN; OBESITY; SPLEEN CELL; ADIPOSE TISSUE; ANIMAL; BLOOD; C57BL MOUSE; DRUG EFFECTS; GENETICS; LIPID DIET; LIPID METABOLISM; LIPOGENESIS; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; SPLEEN;

MUS;

ADIPOSE TISSUE; ALANINE TRANSAMINASE; ANIMALS; ANTIOXIDANTS; ASPARTATE AMINOTRANSFERASES; DIET, HIGH-FAT; DIETARY SUPPLEMENTS; GENE EXPRESSION; LIPID METABOLISM; LIPOGENESIS; LIVER; MALE; MICE; MICE, INBRED C57BL; NF-E2-RELATED FACTOR 2; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; RNA, MESSENGER; SPLEEN; TRIGLYCERIDES; XANTHOPHYLLS;

EID: 84925581758     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114514002554     Document Type: Article

References (46)

1. Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346, 1221-1231.
2. Ludwig J, Viggiano TR, McGill DB, et al. (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55, 434-438.
3. Rector RS, Thyfault JP, Wei Y, et al. (2008) Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 14, 185-192.
4. Marra F, Gastaldelli A, Svegliati Baroni G, et al. (2008) Molecular basis and mechanisms of progression of nonalcoholic steatohepatitis. Trends Mol Med 14, 72-81.
5. Brown WV, Fujioka K, Wilson PW, et al. (2009) Obesity: why be concerned? Am J Med 122, S4-S11.
6. Vernon G, Baranova A & Younossi ZM (2011) Systematic review: the epidemiology and natural history of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34, 274-285.
7. Marchesini G, Bugianesi E, Forlani G, et al. (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37, 917-923.
8. Hussein G, Sankawa U, Goto H, et al. (2006) Astaxanthin, a carotenoid with potential in human health and nutrition. J Nat Prod 69, 443-449.
9. Pashkow FJ, Watumull DG & Campbell CL (2008) Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am J Cardiol 101, 58D-68D.
10. Guerin M, Huntley ME & Olaizola M (2003) Haematococcus astaxanthin: applications for human health and nutrition. Trends Biotechnol 21, 210-216.
11. Goto S, Kogure K, Abe K, et al. (2001) Efficient radical trapping at the surface and inside the phospholipid membrane is responsible for highly potent antiperoxidative activity of the carotenoid astaxanthin. Biochim Biophys Acta 1512, 251-258.
12. Kurashige M, Okimasu E, Inoue M, et al. (1990) Inhibition of oxidative injury of biological membranes by astaxanthin. Physiol Chem Phys Med NMR 22, 27-38.
13. Yang Y, Seo JM, Nguyen A, et al. (2011) Astaxanthin-rich extract from the green alga Haematococcus pluvialis lowers plasma lipid concentrations and enhances antioxidant defense in apolipoprotein E knockout mice. J Nutr 141, 1611-1617.
14. Lee SJ, Bai SK, Lee KS, et al. (2003) Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinase-dependent NF-kappaB activation. Mol Cells 16, 97-105.
15. Uchiyama K, Naito Y, Hasegawa G, et al. (2002) Astaxanthin protects beta-cells against glucose toxicity in diabetic db/db mice. Redox Rep 7, 290-293.
16. Karppi J, Rissanen TH, Nyyssonen K, et al. (2007) Effects of astaxanthin supplementation on lipid peroxidation. Int J Vitam Nutr Res 77, 3-11.
17. Yoshida H, Yanai H, Ito K, et al. (2010) Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia. Atherosclerosis 209, 520-523.
18. Reagan-Shaw S, Nihal M & Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22, 659-661.
19. Rasmussen HE, Blobaum KR, Jesch ED, et al. (2009) Hypocholesterolemic effect of Nostoc commune var. sphaeroides Kutzing, an edible blue-green alga. Eur J Nutr 48, 387-394.
20. Yang Y, Park Y, Cassada DA, et al. (2011) In vitro and in vivo safety assessment of edible blue-green algae, Nostoc commune var. sphaeroides Kützing and Spirulina platensis. Food Chem Toxicol 49, 1560-1564.
21. Rasmussen HE, Blobaum KR, Park YK, et al. (2008) Lipid extract of Nostoc commune var. sphaeroides Kutzing, a blue-green alga, inhibits the activation of sterol regulatory element binding proteins in HepG2 cells. J Nutr 138, 476-481.
22. Park YK, Rasmussen HE, Ehlers SJ, et al. (2008) Repression of proinflammatory gene expression by lipid extract of Nostoc commune var sphaeroides Kutzing, a blue-green alga, via inhibition of nuclear factor-kappaB in RAW 264.7 macrophages. Nutr Res 28, 83-91.
23. Ku CS, Pham TX, Park Y, et al. (2013) Edible blue-green algae reduce the production of pro-inflammatory cytokines by inhibiting NF-kB pathway in macrophages and splenocytes. Biochim Biophys Acta 1830, 2981-2988.
24. Tosello-Trampont AC, Landes SG, Nguyen V, et al. (2012) Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-alpha production. J Biol Chem 287, 40161-40172.
25. Wang C, Yu X, Cao Q, et al. (2013) Characterization of murine macrophages from bone marrow, spleen and peritoneum. BMC Immunol 14, 6.
26. Dowman JK, Tomlinson JW & Newsome PN (2010) Pathogenesis of non-alcoholic fatty liver disease. QJM 103, 71-83.
27. Day CP & James OFW (1998) Steatohepatitis: a tale of two "hits"? Gastroenterology 114, 842-845.
28. Tilg H & Moschen AR (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52, 1836-1846.
29. Bellentani S, Scaglioni F, Marino M, et al. (2010) Epidemiology of non-alcoholic fatty liver disease. Dig Dis 28, 155-161.
30. Fabbrini E, Sullivan S & Klein S (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51, 679-689.
31. Scheig R (1996) Evaluation of tests used to screen patients with liver disorders. Prim Care 23, 551-560.
32. Malmstrom R, Packard CJ, Caslake M, et al. (1997) Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 40, 454-462.
33. Subramanian S & Chait A (2012) Hypertriglyceridemia secondary to obesity and diabetes. Biochim Biophys Acta 1821, 819-825.
34. Hassing HC, Surendran RP, Mooij HL, et al. (2012) Pathophysiology of hypertriglyceridemia. Biochim Biophys Acta 1821, 826-832.
35. Scaglioni F, Ciccia S, Marino M, et al. (2011) ASH and NASH. Dig Dis 29, 202-210.
36. Rashid S, Watanabe T, Sakaue T, et al. (2003) Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 36, 421-429.
37. Lee YS & Jeong WI (2012) Retinoic acids and hepatic stellate cells in liver disease. J Gastroenterol Hepatol 27, Suppl. 2, 75-79.
38. Dooley S, Delvoux B, Lahme B, et al. (2000) Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology 31, 1094-1106.
39. Jang CW, Chen CH, Chen CC, et al. (2002) TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase. Nat Cell Biol 4, 51-58.
40. Bonniaud P, Margetts PJ, Ask K, et al. (2005) TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis. J Immunol 175, 5390-5395.
41. Biernacka A, Dobaczewski M & Frangogiannis NG (2011) TGF-βsignaling in fibrosis. Growth Factors 29, 196-202.
42. Barcellos-Hoff MH & Dix TA (1996) Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol 10, 1077-1083.
43. Hwang S-A, Dasgupta A & Actor JK (2004) Cytokine production by non-adherent mouse splenocyte cultures to Echinacea extracts. Clin Chim Acta 343, 161-166.
44. Aleksunes LM & Manautou JE (2007) Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease. Toxicol Pathol 35, 459-473.
45. Kaspar JW, Niture SK & Jaiswal AK (2009) Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med 47, 1304-1309.
46. Jia Y, Kim JY, Jun HJ, et al. (2012) The natural carotenoid astaxanthin, a PPAR-alpha agonist and PPAR-gamma antagonist, reduces hepatic lipid accumulation by rewiring the transcriptome in lipid-loaded hepatocytes. Mol Nutr Food Res 56, 878-888.